DRUG-CLASS OVERVIEW:@0.982174:0.513429:0.982174:0.311367:0.954164:0.311367:0.954164:0.513429:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.233372:0.041064:0.000000:0.000000:0.019473
187:@0.945393:0.038601:0.984904:0.038601:0.984904:0.019004:0.945393:0.019004:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
cell-surface protein expressed on normal :@0.084848:0.079499:0.481071:0.079499:0.481071:0.063743:0.084848:0.063743:0.012450:0.012508:0.003848:0.003848:0.006388:0.007466:0.011699:0.006716:0.006042:0.013143:0.012450:0.012508:0.008005:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.008005:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.012508:0.013181:0.008005:0.012604:0.011738:0.008005:0.011738:0.012604:0.006315:0.018049:0.013143:0.003848:0.005330
and cancerous B- and T-lymphocytes.  By :@0.084848:0.094964:0.481078:0.094964:0.481078:0.079208:0.084848:0.079208:0.013143:0.011738:0.013181:0.004984:0.012450:0.013143:0.011738:0.012450:0.012508:0.005709:0.012604:0.011699:0.007466:0.004984:0.011045:0.006388:0.004984:0.013143:0.011738:0.013181:0.004984:0.008197:0.006388:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.012450:0.010314:0.006523:0.012508:0.007466:0.005330:0.012445:0.004984:0.011045:0.010314:0.005330
48:@0.436970:0.089345:0.449400:0.089345:0.449400:0.080159:0.436970:0.080159:0.006215:0.006215
binding to CD52, alemtuzumab causes ly-:@0.084857:0.110429:0.475767:0.110429:0.475767:0.094673:0.084857:0.094673:0.013123:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.005907:0.006523:0.012604:0.005890:0.015644:0.014316:0.010660:0.010660:0.005330:0.005898:0.013143:0.003848:0.012508:0.018049:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.005896:0.012450:0.013143:0.011699:0.007466:0.012508:0.007466:0.005907:0.003848:0.010314:0.006388
sis to the lymphocytes via complemented :@0.084857:0.125894:0.481116:0.125894:0.481116:0.110138:0.084857:0.110138:0.007466:0.003848:0.007466:0.005715:0.006523:0.012604:0.005715:0.006523:0.011738:0.012508:0.005715:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.012450:0.010314:0.006523:0.012508:0.007466:0.005715:0.010660:0.003848:0.013143:0.005715:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.018049:0.012508:0.011738:0.006523:0.012508:0.013181:0.005330
fixation  and  antibody-dependent,  cell-:@0.084857:0.141359:0.475759:0.141359:0.475759:0.125603:0.084857:0.125603:0.004686:0.004686:0.009236:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.009379:0.013143:0.011738:0.013181:0.005330:0.009388:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.006388:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.012508:0.011738:0.006523:0.005330:0.005330:0.009377:0.012450:0.012508:0.003848:0.003848:0.006388
mediated cytotoxicity.  Alemtuzumab is :@0.084857:0.156824:0.481087:0.156824:0.481087:0.141068:0.084857:0.141068:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.013181:0.010198:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330:0.012420:0.010198:0.014239:0.003848:0.012508:0.018049:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.010198:0.003848:0.007466:0.773598
48:@0.300551:0.151205:0.312981:0.151205:0.312981:0.142019:0.300551:0.142019:0.006215:0.006215
used in the treatment of chronic lympho-:@0.084847:0.172289:0.475749:0.172289:0.475749:0.156533:0.084847:0.156533:0.011699:0.007466:0.012508:0.013181:0.006870:0.003848:0.011738:0.006870:0.006523:0.011738:0.012508:0.006870:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006870:0.012604:0.006042:0.006870:0.012450:0.011738:0.005711:0.012604:0.011738:0.003848:0.012450:0.006870:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.006388
cytic leukaemia and in fludarabine-refrac-:@0.084847:0.187753:0.475760:0.187753:0.475760:0.171998:0.084847:0.171998:0.012450:0.010314:0.006523:0.003848:0.012450:0.004337:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.004333:0.013143:0.011738:0.013181:0.004335:0.003848:0.011738:0.004335:0.004666:0.004666:0.011699:0.013181:0.013143:0.005792:0.013143:0.013123:0.003848:0.011738:0.012508:0.006388:0.005715:0.012508:0.006042:0.005792:0.013143:0.012450:0.006388
tory patients.:@0.084847:0.203218:0.206671:0.203218:0.206671:0.187462:0.084847:0.187462:0.006523:0.012604:0.005792:0.010314:0.006388:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
48,49:@0.206663:0.197599:0.234630:0.197599:0.234630:0.188414:0.206663:0.188414:0.006215:0.006215:0.003107:0.006215:0.006215
 Side effects include tran-:@0.234638:0.203219:0.475760:0.203219:0.475760:0.187463:0.234638:0.187463:0.006388:0.009583:0.003848:0.013181:0.012508:0.006388:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.006388:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.006388:0.006523:0.005792:0.013143:0.011738:0.006388
sient neutropaenia, the risk of opportunistic :@0.084855:0.218683:0.481102:0.218683:0.481102:0.202927:0.084855:0.202927:0.007466:0.003848:0.012508:0.011738:0.006523:0.003541:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.003541:0.006523:0.011738:0.012508:0.003541:0.005792:0.003848:0.007466:0.009660:0.003541:0.012604:0.006042:0.003541:0.012604:0.013123:0.013123:0.012604:0.005792:0.006523:0.011699:0.011738:0.003848:0.007466:0.006523:0.003848:0.012450:0.005330
infection, fever, rigors, chills, bronchos-:@0.084855:0.234148:0.475764:0.234148:0.475764:0.218392:0.084855:0.218392:0.003848:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.014336:0.006042:0.012508:0.010660:0.012508:0.003768:0.005330:0.014336:0.005792:0.003848:0.012950:0.012604:0.005792:0.007466:0.005330:0.014336:0.012450:0.011738:0.003848:0.003848:0.003848:0.007478:0.005330:0.014336:0.013123:0.005715:0.012604:0.011738:0.012450:0.011738:0.012604:0.007439:0.006388
pasm, hypotension, angio-oedema and :@0.084855:0.249613:0.481085:0.249613:0.481085:0.233857:0.084855:0.233857:0.013123:0.013143:0.007466:0.018049:0.005330:0.011180:0.011738:0.010314:0.013123:0.012604:0.006523:0.012508:0.011728:0.007466:0.003848:0.012604:0.011738:0.005330:0.011180:0.013143:0.011738:0.012950:0.003848:0.012604:0.006388:0.012604:0.012508:0.013181:0.012508:0.018049:0.013143:0.011180:0.013143:0.011738:0.013181:0.005330
acute lung injury.  :@0.084855:0.265078:0.262443:0.265078:0.262443:0.249322:0.084855:0.249322:0.013143:0.012450:0.011699:0.006523:0.012508:0.005330:0.003848:0.011699:0.011738:0.012950:0.005330:0.003848:0.011738:0.003906:0.011699:0.005792:0.010314:0.005330:0.012412:0.834781
48:@0.244679:0.259459:0.257109:0.259459:0.257109:0.250274:0.244679:0.250274:0.006215:0.006215
Bevacizumab:@0.084848:0.295450:0.226815:0.295450:0.226815:0.277429:0.084848:0.277429:0.012401:0.013683:0.011973:0.014111:0.013683:0.005131:0.009835:0.012828:0.020098:0.014111:0.014111
Bevacizumab binds to VEGF and blocks its :@0.084848:0.313531:0.481073:0.313531:0.481073:0.297775:0.084848:0.297775:0.011045:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.004938:0.013123:0.003848:0.011738:0.013181:0.007466:0.004938:0.006523:0.012604:0.004926:0.013508:0.010314:0.016779:0.009333:0.004926:0.013143:0.011738:0.013181:0.004926:0.013123:0.003848:0.012604:0.012450:0.009660:0.007466:0.004926:0.003848:0.006523:0.007466:0.005330
biological activities by preventing it from :@0.084848:0.328996:0.481090:0.328996:0.481090:0.313240:0.084848:0.313240:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.008063:0.013143:0.012450:0.006523:0.003848:0.010660:0.003848:0.006523:0.003848:0.012508:0.007466:0.008063:0.013123:0.010314:0.008063:0.013123:0.005715:0.012508:0.010660:0.012508:0.011738:0.006523:0.003848:0.011738:0.012950:0.008049:0.003848:0.006523:0.008063:0.006042:0.005711:0.012604:0.018049:0.005330
binding with its receptor, VEGFR, on the :@0.084848:0.344461:0.481073:0.344461:0.481073:0.328705:0.084848:0.328705:0.013123:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.009660:0.015990:0.003848:0.006523:0.011738:0.009660:0.003848:0.006523:0.007466:0.009660:0.005711:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.003760:0.005330:0.009660:0.013508:0.010314:0.016779:0.009333:0.011680:0.005330:0.009660:0.012604:0.011738:0.009660:0.006523:0.011738:0.012508:0.005330
vascular endothelium.:@0.084848:0.359926:0.303288:0.359926:0.303288:0.344170:0.084848:0.344170:0.010660:0.013143:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.016664:0.012508:0.011738:0.013181:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.011699:0.018049:0.005330
26,39:@0.303274:0.354307:0.331241:0.354307:0.331241:0.345121:0.303274:0.345121:0.006215:0.006215:0.003107:0.006215:0.006215
  Bevacizumab :@0.331248:0.359926:0.481077:0.359926:0.481077:0.344170:0.331248:0.344170:0.005330:0.011322:0.011045:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330
inhibits vascular permeability, but increas-:@0.084849:0.375391:0.475739:0.375391:0.475739:0.359635:0.084849:0.359635:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007466:0.005869:0.010660:0.013143:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.005857:0.013123:0.012508:0.006325:0.018049:0.012508:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.005330:0.005869:0.013123:0.011699:0.006523:0.005869:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.006388
es tumour blood flow and therefore drug :@0.084849:0.390856:0.481114:0.390856:0.481114:0.375100:0.084849:0.375100:0.012508:0.007466:0.007299:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007291:0.013123:0.003848:0.012604:0.012604:0.013181:0.007299:0.004666:0.004666:0.012604:0.015990:0.007291:0.013143:0.011738:0.013181:0.007299:0.006523:0.011738:0.012508:0.005713:0.012508:0.006042:0.012604:0.005705:0.012508:0.007297:0.013181:0.005792:0.011699:0.012950:0.005330
delivery.  Bevacizumab is indicated in the :@0.084849:0.406320:0.481113:0.406320:0.481113:0.390565:0.084849:0.390565:0.013181:0.012508:0.003848:0.003848:0.010660:0.012508:0.005792:0.010314:0.005330:0.006221:0.006158:0.011045:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.006158:0.003848:0.007466:0.006158:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.006158:0.003848:0.011738:0.006158:0.006523:0.011738:0.012508:0.410668
4:@0.162842:0.400701:0.169057:0.400701:0.169057:0.391516:0.162842:0.391516:0.006215
treatment of colorectal cancer, breast :@0.084855:0.421785:0.481094:0.421785:0.481094:0.406029:0.084855:0.406029:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.013373:0.012604:0.006042:0.013373:0.012450:0.012604:0.003848:0.012604:0.005707:0.012508:0.012450:0.006523:0.013143:0.003848:0.013373:0.012450:0.013143:0.011738:0.012450:0.012508:0.003766:0.005330:0.013373:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330
cancer,  non-small-cell lung  cancer  and :@0.084855:0.437250:0.481096:0.437250:0.481096:0.421494:0.084855:0.421494:0.012450:0.013143:0.011738:0.012450:0.012508:0.003764:0.005330:0.005330:0.005990:0.011738:0.012604:0.011738:0.006388:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.011334:0.003848:0.011699:0.011738:0.012950:0.005330:0.005988:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.005984:0.013143:0.011738:0.013181:0.005330
renal cancer.   Side effects  of  MAbs in-:@0.084855:0.452715:0.475770:0.452715:0.475770:0.436959:0.084855:0.436959:0.005713:0.012508:0.011738:0.013143:0.003848:0.011661:0.012450:0.013143:0.011738:0.012450:0.012508:0.004374:0.005330:0.006200:0.005330:0.006321:0.009583:0.003848:0.013181:0.012508:0.011661:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330:0.006319:0.012604:0.006042:0.005330:0.006315:0.017684:0.014239:0.013123:0.007466:0.011661:0.003848:0.011738:0.349586
4:@0.215440:0.447096:0.221655:0.447096:0.221655:0.437911:0.215440:0.437911:0.006215
clude hypertension, infusion reactions, ar-:@0.084843:0.468180:0.475789:0.468180:0.475789:0.452424:0.084843:0.452424:0.012450:0.003848:0.011699:0.013181:0.012508:0.006600:0.011738:0.010314:0.013123:0.012508:0.005792:0.006523:0.012508:0.011738:0.007466:0.003848:0.012604:0.011738:0.005330:0.006600:0.003848:0.011738:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.006600:0.005713:0.012508:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006600:0.013143:0.005792:0.006388
terial thrombo-embolic events, GI perfora-:@0.084843:0.483645:0.475776:0.483645:0.475776:0.467889:0.084843:0.467889:0.006523:0.012508:0.005792:0.003848:0.013143:0.003848:0.004483:0.006523:0.011738:0.005707:0.012604:0.018049:0.013123:0.012604:0.006388:0.012508:0.018049:0.013123:0.012604:0.003848:0.003848:0.012450:0.004483:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.005330:0.004483:0.016779:0.004349:0.004483:0.013123:0.012508:0.006708:0.006042:0.012604:0.005792:0.013143:0.006388
tions, wound-healing complications and :@0.084843:0.499110:0.481083:0.499110:0.481083:0.483354:0.084843:0.483354:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.010757:0.015990:0.012604:0.011699:0.011738:0.013181:0.006388:0.011738:0.012508:0.013143:0.003848:0.003848:0.011738:0.012950:0.010757:0.012450:0.012604:0.018049:0.013123:0.003848:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.010757:0.013143:0.011738:0.013181:0.005330
proteinuria.:@0.084843:0.514575:0.190715:0.514575:0.190715:0.498819:0.084843:0.498819:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.011699:0.005792:0.003848:0.013143:0.005330
4:@0.190710:0.508956:0.196925:0.508956:0.196925:0.499770:0.190710:0.499770:0.006215
Cetuximab :@0.084848:0.544946:0.205862:0.544946:0.205862:0.526925:0.084848:0.526925:0.016677:0.013683:0.006414:0.012828:0.011973:0.005131:0.020098:0.014111:0.014111:0.005987
Cetuximab  is a  recombinant,  human/:@0.084848:0.563028:0.475767:0.563028:0.475767:0.547272:0.084848:0.547272:0.015644:0.012508:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.005330:0.009956:0.003848:0.007466:0.015298:0.013143:0.005330:0.009956:0.005711:0.012508:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.011738:0.006523:0.005330:0.005330:0.009946:0.011738:0.011699:0.018049:0.013143:0.011738:0.008409
mouse  chimeric  MAb  that  binds  specifi-:@0.084848:0.578492:0.475752:0.578492:0.475752:0.562737:0.084848:0.562737:0.018049:0.012604:0.011699:0.007466:0.012508:0.005330:0.004749:0.012450:0.011738:0.003848:0.018049:0.012508:0.005792:0.003848:0.012450:0.005330:0.004753:0.017684:0.014239:0.013123:0.005330:0.004749:0.006523:0.011738:0.013143:0.006523:0.005330:0.004749:0.013123:0.003848:0.011738:0.013181:0.007466:0.005330:0.004759:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.006388
cally  to the extracellular domain of the :@0.084848:0.593957:0.481086:0.593957:0.481086:0.578201:0.084848:0.578201:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.004866:0.006523:0.012604:0.010179:0.006523:0.011738:0.012508:0.010179:0.012508:0.009236:0.006523:0.005792:0.013143:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.010179:0.013181:0.012604:0.018049:0.013143:0.003848:0.011738:0.010179:0.012604:0.006042:0.010179:0.006523:0.011738:0.012508:0.005330
EGFR, preventing binding of EGF.:@0.084848:0.609422:0.395049:0.609422:0.395049:0.593666:0.084848:0.593666:0.010314:0.016779:0.009333:0.011680:0.005330:0.006542:0.013123:0.005713:0.012508:0.010660:0.012508:0.011738:0.006523:0.003848:0.011738:0.012950:0.006533:0.013123:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.006542:0.012604:0.006042:0.006533:0.010314:0.016779:0.007809:0.005330
26,39:@0.395038:0.603803:0.423005:0.603803:0.423005:0.594618:0.395038:0.594618:0.006215:0.006215:0.003107:0.006215:0.006215
 Bind-:@0.423012:0.609422:0.475755:0.609422:0.475755:0.593666:0.423012:0.593666:0.006542:0.011045:0.003848:0.011738:0.013181:0.006388
ing to the receptor blocks phosphorylation :@0.084846:0.624887:0.481107:0.624887:0.481107:0.609131:0.084846:0.609131:0.003848:0.011738:0.012950:0.004387:0.006523:0.012604:0.004387:0.006523:0.011738:0.012508:0.004387:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.004372:0.013123:0.003848:0.012604:0.012450:0.009660:0.007466:0.004387:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.012604:0.005792:0.010314:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
and activation of receptor-associated  ki-:@0.084846:0.640352:0.475780:0.640352:0.475780:0.624596:0.084846:0.624596:0.013143:0.011738:0.013181:0.005984:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.005984:0.012604:0.006042:0.005973:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.006388:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.005984:0.005984:0.009660:0.003848:0.006388
nases, which results in inhibition of cell :@0.084846:0.655817:0.481064:0.655817:0.481064:0.640061:0.084846:0.640061:0.011738:0.013143:0.007466:0.012508:0.007466:0.005330:0.012084:0.015990:0.011738:0.003848:0.012450:0.011738:0.012084:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.012084:0.003848:0.011738:0.012084:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.012604:0.011738:0.012084:0.012604:0.006042:0.012084:0.012450:0.012508:0.003848:0.003848:0.005330
growth, motility, invasiveness, metastasis :@0.084846:0.671282:0.481080:0.671282:0.481080:0.655526:0.084846:0.655526:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.005330:0.011545:0.018049:0.012604:0.006523:0.003848:0.003848:0.003848:0.006523:0.010314:0.005330:0.011545:0.003848:0.011738:0.010660:0.013143:0.007466:0.003848:0.010660:0.012508:0.011738:0.012508:0.007466:0.007485:0.005330:0.011545:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.003848:0.007466:0.005330
and promotes apoptosis.:@0.084846:0.686747:0.331582:0.686747:0.331582:0.670991:0.084846:0.670991:0.013143:0.011738:0.013181:0.012431:0.013123:0.005715:0.012604:0.018049:0.012604:0.006523:0.012508:0.007456:0.012431:0.013143:0.013123:0.012604:0.013123:0.006523:0.012604:0.007466:0.003848:0.007466:0.005330
26,39:@0.331581:0.681128:0.359548:0.681128:0.359548:0.671943:0.331581:0.671943:0.006215:0.006215:0.003107:0.006215:0.006215
 Cetuximab :@0.359555:0.686747:0.481090:0.686747:0.481090:0.670991:0.359555:0.670991:0.012431:0.015644:0.012508:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.005330
decreases the production  of  VEGF and :@0.084850:0.702212:0.481102:0.702212:0.481102:0.686456:0.084850:0.686456:0.013181:0.012508:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.007466:0.010622:0.006523:0.011738:0.012508:0.010622:0.013123:0.005715:0.012604:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005278:0.012604:0.006042:0.005330:0.005282:0.013508:0.010314:0.016779:0.009333:0.010622:0.013143:0.011738:0.013181:0.005330
enhances the response to radio- or chem-:@0.084850:0.717677:0.475777:0.717677:0.475777:0.701921:0.084850:0.701921:0.012508:0.011738:0.011738:0.013143:0.011738:0.012450:0.012508:0.007466:0.005022:0.006523:0.011738:0.012508:0.005022:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005022:0.006523:0.012604:0.005022:0.005792:0.013143:0.013181:0.003848:0.012604:0.006388:0.005022:0.012604:0.005792:0.005022:0.012450:0.011738:0.012508:0.018049:0.006388
otherapy.:@0.084850:0.733142:0.175925:0.733142:0.175925:0.717386:0.084850:0.717386:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
4,26:@0.175912:0.727523:0.197664:0.727523:0.197664:0.718337:0.175912:0.718337:0.006215:0.003107:0.006215:0.006215
 Unfortunately, it targets EGFR :@0.197669:0.733142:0.481104:0.733142:0.481104:0.717386:0.197669:0.717386:0.006081:0.012604:0.011738:0.006042:0.012604:0.005792:0.006523:0.011699:0.011738:0.013143:0.006523:0.012508:0.003848:0.010314:0.005330:0.006058:0.003848:0.006523:0.006081:0.006523:0.013143:0.005809:0.012950:0.012508:0.006523:0.007466:0.006081:0.010314:0.016779:0.009333:0.011680:0.005330
on both normal and cancer cells.:@0.084851:0.748607:0.397103:0.748607:0.397103:0.732851:0.084851:0.732851:0.012604:0.011738:0.005330:0.013123:0.012604:0.006523:0.011738:0.005330:0.011738:0.012604:0.006298:0.018049:0.013143:0.003848:0.005330:0.013143:0.011738:0.013181:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330
26:@0.397096:0.742988:0.409526:0.742988:0.409526:0.733802:0.397096:0.733802:0.006215:0.006215
Cetuximab  is indicated  for  the  treat-:@0.103030:0.764072:0.475765:0.764072:0.475765:0.748316:0.103030:0.748316:0.015644:0.012508:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.005330:0.006916:0.003848:0.007466:0.012257:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330:0.006918:0.006042:0.012604:0.005792:0.005330:0.006906:0.006523:0.011738:0.012508:0.005330:0.006906:0.006523:0.005711:0.012508:0.013143:0.006523:0.006388
ment of colorectal cancer, as an adjunct :@0.084846:0.779537:0.481089:0.779537:0.481089:0.763781:0.084846:0.763781:0.018049:0.012508:0.011738:0.006523:0.006369:0.012604:0.006042:0.006375:0.012450:0.012604:0.003848:0.012604:0.005709:0.012508:0.012450:0.006523:0.013143:0.003848:0.006379:0.012450:0.013143:0.011738:0.012450:0.012508:0.003764:0.005330:0.006375:0.013143:0.007466:0.006377:0.013143:0.011738:0.006377:0.013143:0.013181:0.003906:0.011699:0.011738:0.012450:0.006523:0.005330
to radiotherapy in head and neck cancer :@0.084846:0.795002:0.481095:0.795002:0.481095:0.779246:0.084846:0.779246:0.006523:0.012604:0.005234:0.005792:0.013143:0.013181:0.003848:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005236:0.003848:0.011738:0.005244:0.011738:0.012508:0.013143:0.013181:0.005240:0.013143:0.011738:0.013181:0.005242:0.011738:0.012508:0.012450:0.009660:0.005238:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
and  non-small-cell lung  cancer.   Side ef-:@0.084846:0.810466:0.475767:0.810466:0.475767:0.794711:0.084846:0.794711:0.013143:0.011738:0.013181:0.005330:0.003165:0.011738:0.012604:0.011738:0.006388:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.008505:0.003848:0.011699:0.011738:0.012950:0.005330:0.003162:0.012450:0.013143:0.011738:0.012450:0.012508:0.004378:0.005330:0.006211:0.005330:0.003165:0.009583:0.003848:0.013181:0.012508:0.008505:0.012508:0.006042:-0.170776
4:@0.388491:0.804848:0.394706:0.804848:0.394706:0.795662:0.388491:0.795662:0.006215
fects of cetuximab include infusion reac-:@0.084848:0.825931:0.475755:0.825931:0.475755:0.810175:0.084848:0.810175:0.006042:0.012508:0.012450:0.006523:0.007466:0.007647:0.012604:0.006042:0.007643:0.012450:0.012508:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.007649:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007649:0.003848:0.011738:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.007649:0.005711:0.012508:0.013143:0.012450:0.006388
tions,  skin rash,  hypomagnesaemia, fa-:@0.084848:0.841396:0.475769:0.841396:0.475769:0.825640:0.084848:0.825640:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.005330:0.007664:0.007466:0.009660:0.003848:0.011738:0.013008:0.005792:0.013143:0.007466:0.011738:0.005330:0.005330:0.007664:0.011738:0.010314:0.013123:0.012604:0.018049:0.013143:0.012950:0.011738:0.012508:0.007466:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.013008:0.006042:0.013143:0.006388
tigue and interstitial lung disease.:@0.084848:0.856861:0.393053:0.856861:0.393053:0.841105:0.084848:0.841105:0.006523:0.003848:0.012950:0.011699:0.012508:0.005330:0.013143:0.011738:0.013181:0.005330:0.003848:0.011738:0.006523:0.012508:0.005792:0.007466:0.006523:0.003848:0.006523:0.003848:0.013143:0.003848:0.005330:0.003848:0.011699:0.011738:0.012950:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
4:@0.393046:0.851242:0.399261:0.851242:0.399261:0.842057:0.393046:0.842057:0.006215
Rituximab :@0.084848:0.887233:0.193033:0.887233:0.193033:0.869211:0.084848:0.869211:0.012401:0.005131:0.006414:0.012828:0.011973:0.005131:0.020098:0.014111:0.014111:0.005987
The immunomodulating MAb, rituximab, is :@0.084848:0.905314:0.481084:0.905314:0.481084:0.889558:0.084848:0.889558:0.008197:0.011738:0.012508:0.005648:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.018049:0.012590:0.013181:0.011699:0.003848:0.013143:0.006523:0.003848:0.011738:0.012950:0.005657:0.017684:0.014239:0.013123:0.005330:0.005657:0.005792:0.003848:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.005330:0.005657:0.003848:0.007466:0.005330
a cytotoxic  MAb  that  binds to  CD20, a :@0.084848:0.920779:0.481084:0.920779:0.481084:0.905023:0.084848:0.905023:0.013143:0.010006:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.005330:0.004664:0.017684:0.014239:0.013123:0.005330:0.004666:0.006523:0.011738:0.013143:0.006523:0.005330:0.004666:0.013123:0.003848:0.011738:0.013181:0.007466:0.010006:0.006523:0.012604:0.005330:0.004664:0.015644:0.014316:0.010660:0.010660:0.005330:0.010006:0.013143:0.005330
cell-surface marker expressed by mature :@0.084848:0.936244:0.481090:0.936244:0.481090:0.920488:0.084848:0.920488:0.012450:0.012508:0.003848:0.003848:0.006388:0.007466:0.011699:0.006716:0.006042:0.013143:0.012450:0.012508:0.008030:0.018049:0.013143:0.005792:0.009660:0.012508:0.005792:0.008020:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.012508:0.013181:0.008032:0.013123:0.010314:0.008043:0.018049:0.013143:0.006523:0.011699:0.005709:0.012508:0.005330
B-lymphocytes, some leukaemias and non- :@0.524249:0.079497:0.920469:0.079497:0.920469:0.063741:0.524249:0.063741:0.010853:0.006196:0.003656:0.010122:0.017857:0.012931:0.011545:0.012411:0.012257:0.010122:0.006331:0.012315:0.007274:0.005138:0.004676:0.007274:0.012411:0.017857:0.012315:0.004676:0.003656:0.012315:0.011507:0.009467:0.012950:0.012315:0.017857:0.003656:0.012950:0.007274:0.004676:0.012950:0.011545:0.012989:0.004676:0.011545:0.012411:0.011545:0.006388:0.005330
Hodgkin’s lymphomas.:@0.524249:0.095001:0.736666:0.095001:0.736666:0.079245:0.524249:0.079245:0.012950:0.012411:0.012989:0.012758:0.009467:0.003656:0.011545:0.006562:0.007274:0.010872:0.003656:0.010122:0.017857:0.012931:0.011545:0.012411:0.017857:0.012950:0.007274:0.005330
1,4,26:@0.736476:0.089382:0.766990:0.089382:0.766990:0.080197:0.736476:0.080197:0.006103:0.002995:0.006103:0.002995:0.006103:0.006215
 Binding of the :@0.766883:0.095001:0.920474:0.095001:0.920474:0.079245:0.766883:0.079245:0.010872:0.010853:0.003656:0.011545:0.012989:0.003656:0.011545:0.012758:0.010872:0.012411:0.005850:0.010872:0.006331:0.011545:0.012506:0.005330
MAb to CD20 leads to apoptosis of the :@0.524236:0.110506:0.920493:0.110506:0.920493:0.094750:0.524236:0.094750:0.017491:0.014047:0.012931:0.010352:0.006331:0.012411:0.010352:0.015452:0.014124:0.010468:0.010468:0.010352:0.003656:0.012315:0.012950:0.012989:0.007274:0.010352:0.006331:0.012411:0.010352:0.012950:0.012931:0.012411:0.012931:0.006331:0.012411:0.007274:0.003656:0.007274:0.010352:0.012411:0.005850:0.010352:0.006331:0.011545:0.012506:0.005330
CD20-positive cells.  Side effects of rituxi-:@0.524236:0.126010:0.915148:0.126006:0.915148:0.110250:0.524236:0.110255:0.015452:0.014124:0.010468:0.010468:0.006196:0.012931:0.012411:0.007274:0.003656:0.006331:0.003656:0.010468:0.012315:0.008717:0.012257:0.012315:0.003656:0.003656:0.007274:0.005330:0.012050:0.008717:0.009390:0.003656:0.012989:0.012315:0.008717:0.012315:0.005905:0.005850:0.012315:0.012257:0.006331:0.007274:0.008717:0.012411:0.005850:0.008717:0.005600:0.003656:0.006331:0.011507:0.009044:0.003656:0.385421
26:@0.703031:0.120387:0.715349:0.120387:0.715349:0.111201:0.703031:0.111201:0.006103:0.006215
mab are rare, with most patients only de-:@0.524241:0.141510:0.915166:0.141510:0.915166:0.125755:0.524241:0.125755:0.017857:0.012950:0.012931:0.007274:0.012950:0.005521:0.012315:0.007274:0.005600:0.012950:0.005521:0.012315:0.005138:0.007274:0.015798:0.003656:0.006331:0.011545:0.007274:0.017857:0.012411:0.007274:0.006331:0.007274:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.007274:0.012411:0.011545:0.003656:0.010122:0.007274:0.012989:0.012315:0.006388
veloping a rash after the initial treatment.:@0.524241:0.157015:0.900640:0.157015:0.900640:0.141259:0.524241:0.141259:0.010468:0.012315:0.003656:0.012411:0.012931:0.003656:0.011545:0.012758:0.005138:0.012950:0.005138:0.005600:0.012950:0.007274:0.011545:0.005138:0.012950:0.005850:0.006331:0.012315:0.005600:0.005138:0.006331:0.011545:0.012315:0.005138:0.003656:0.011545:0.003656:0.006331:0.003656:0.012950:0.003656:0.005138:0.006331:0.005521:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.005330
4:@0.900417:0.151392:0.906632:0.151392:0.906632:0.142206:0.900417:0.142206:0.006215
Trastuzumab :@0.524242:0.187457:0.659794:0.187457:0.659794:0.169436:0.524242:0.169436:0.008980:0.006842:0.014111:0.009407:0.006414:0.012828:0.009835:0.012828:0.020098:0.014111:0.014111:0.005987
Trastuzumab is a recombinant MAb that :@0.524242:0.205576:0.920479:0.205576:0.920479:0.189820:0.524242:0.189820:0.007620:0.005792:0.013143:0.007466:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.009121:0.003848:0.007466:0.009121:0.013143:0.009121:0.005713:0.012508:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.011738:0.006523:0.009121:0.017684:0.014239:0.013123:0.009121:0.006523:0.011738:0.013143:0.006523:0.005330
binds to the extracellular segment of the :@0.524242:0.221080:0.920501:0.221080:0.920501:0.205324:0.524242:0.205324:0.013123:0.003848:0.011738:0.013181:0.007466:0.007697:0.006523:0.012604:0.007697:0.006523:0.011738:0.012508:0.007697:0.012508:0.009236:0.006523:0.005792:0.013143:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.007697:0.007466:0.012508:0.012950:0.018049:0.012508:0.011738:0.006523:0.007697:0.012604:0.006042:0.007697:0.006523:0.011738:0.012508:0.005330
HER2.  Binding of the antibody to the  re-:@0.524242:0.236585:0.915167:0.236580:0.915167:0.220824:0.524242:0.220829:0.013143:0.010314:0.011680:0.010660:0.005330:0.012439:0.006331:0.011045:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.006331:0.012604:0.006042:0.006331:0.006523:0.011738:0.012508:0.006321:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.006331:0.006523:0.012604:0.006321:0.006523:0.011738:0.012508:0.006321:0.006331:0.005713:0.012508:0.224567
26:@0.575373:0.230961:0.587803:0.230961:0.587803:0.221776:0.575373:0.221776:0.006215:0.006215
ceptor inhibits DNA repair and cell prolif-:@0.524250:0.252085:0.915148:0.252085:0.915148:0.236329:0.524250:0.236329:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.007755:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007466:0.007772:0.014316:0.014239:0.014239:0.007755:0.005713:0.012508:0.013123:0.013143:0.003848:0.005792:0.007755:0.013143:0.011738:0.013181:0.007755:0.012450:0.012508:0.003848:0.003848:0.007766:0.013123:0.005715:0.012604:0.003848:0.003848:0.006042:0.006388
eration, arresting the cell cycle at the G -:@0.524250:0.267589:0.915150:0.267585:0.915150:0.251829:0.524250:0.251833:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.006113:0.013143:0.005792:0.005711:0.012508:0.007466:0.006523:0.003848:0.011738:0.012950:0.006123:0.006523:0.011738:0.012508:0.006117:0.012450:0.012508:0.003848:0.003848:0.006138:0.012450:0.010314:0.012450:0.003848:0.012508:0.006129:0.013143:0.006523:0.006125:0.006523:0.011738:0.012508:0.006119:0.016779:0.008276:0.179486
1:@0.900472:0.271341:0.908759:0.271341:0.908759:0.259093:0.900472:0.259093:0.008287
phase, which leads to  the  induction  of :@0.524241:0.283089:0.920497:0.283089:0.920497:0.267334:0.524241:0.267334:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.010930:0.015990:0.011738:0.003848:0.012450:0.011738:0.010930:0.003848:0.012508:0.013143:0.013181:0.007466:0.010930:0.006523:0.012604:0.005330:0.005586:0.006523:0.011738:0.012508:0.005330:0.005586:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005586:0.012604:0.006042:0.005330
apoptosis in the cell.  Furthermore, trastu-:@0.524241:0.298594:0.915156:0.298590:0.915156:0.282834:0.524241:0.282838:0.013143:0.013123:0.012604:0.013123:0.006523:0.012604:0.007466:0.003848:0.007466:0.005734:0.003848:0.011738:0.005723:0.006523:0.011738:0.012508:0.005721:0.012450:0.012508:0.003848:0.003848:0.005330:0.012425:0.005721:0.009333:0.011699:0.005792:0.006523:0.011738:0.012508:0.006308:0.018049:0.012604:0.005709:0.012508:0.005330:0.005717:0.006523:0.005792:0.013143:0.007466:0.006523:0.011699:0.134382
39:@0.715649:0.292971:0.728079:0.292971:0.728079:0.283785:0.715649:0.283785:0.006215:0.006215
zumab suppresses angiogenesis as it has :@0.524249:0.314094:0.920456:0.314094:0.920456:0.298338:0.524249:0.298338:0.008178:0.011699:0.018049:0.013143:0.013123:0.008409:0.007466:0.011699:0.013123:0.013123:0.005721:0.012508:0.007466:0.007466:0.012508:0.007466:0.008409:0.013143:0.011738:0.012950:0.003848:0.012604:0.012950:0.012508:0.011738:0.012508:0.007466:0.003848:0.007466:0.008409:0.013143:0.007466:0.008409:0.003848:0.006523:0.008409:0.011738:0.013143:0.007466:0.005330
anti-angiogenic properties preventing :@0.524249:0.329599:0.920507:0.329599:0.920507:0.313843:0.524249:0.313843:0.013143:0.011738:0.006523:0.003848:0.006388:0.013143:0.011738:0.012950:0.003848:0.012604:0.012950:0.012508:0.011738:0.003848:0.012450:0.023495:0.013123:0.005715:0.012604:0.013123:0.012508:0.005792:0.006523:0.003848:0.012508:0.007466:0.023495:0.013123:0.005715:0.012508:0.010660:0.012508:0.011738:0.006523:0.003848:0.011738:0.012950:0.005330
new vessel formation required for tumour :@0.524249:0.345103:0.920504:0.345103:0.920504:0.329347:0.524249:0.329347:0.011738:0.012508:0.015990:0.007254:0.010660:0.012508:0.007466:0.007466:0.012508:0.003848:0.007254:0.006042:0.012604:0.006319:0.018049:0.013143:0.006523:0.003848:0.012604:0.011738:0.007254:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.013181:0.007254:0.006042:0.012604:0.005792:0.007245:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330
growth.:@0.524249:0.360608:0.595093:0.360608:0.595093:0.344852:0.524249:0.344852:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.005330
26,39:@0.595076:0.354980:0.623043:0.354980:0.623043:0.345794:0.595076:0.345794:0.006215:0.006215:0.003107:0.006215:0.006215
 Trastuzumab is indicated for :@0.623050:0.360599:0.920480:0.360599:0.920480:0.344843:0.623050:0.344843:0.012373:0.007620:0.005792:0.013143:0.007466:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.012373:0.003848:0.007466:0.012373:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.012373:0.006042:0.012604:0.005792:0.005330
the treatment of metastatic breast cancer :@0.524241:0.376104:0.920498:0.376104:0.920498:0.360348:0.524241:0.360348:0.006523:0.011738:0.012508:0.004310:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004310:0.012604:0.006042:0.004310:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.004310:0.013123:0.005717:0.012508:0.013143:0.007466:0.006523:0.004310:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
with HER2 overexpression (in men  and :@0.524241:0.391608:0.920484:0.391608:0.920484:0.375852:0.524241:0.375852:0.015990:0.003848:0.006523:0.011738:0.013258:0.013143:0.010314:0.011680:0.010660:0.013258:0.012604:0.010660:0.012508:0.005711:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.013258:0.007100:0.003848:0.011738:0.013258:0.018049:0.012508:0.011738:0.005330:0.007918:0.013143:0.011738:0.013181:0.005330
women).:@0.524241:0.407113:0.607560:0.407113:0.607560:0.391357:0.524241:0.391357:0.015990:0.012604:0.018049:0.012508:0.011738:0.007100:0.005330
39,92:@0.607553:0.401487:0.635521:0.401487:0.635521:0.392301:0.607553:0.392301:0.006215:0.006215:0.003107:0.006215:0.006215
 Side effects of trastuzumab :@0.635528:0.407106:0.920504:0.407106:0.920504:0.391350:0.635528:0.391350:0.010737:0.009583:0.003848:0.013181:0.012508:0.010737:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.010737:0.012604:0.006042:0.010737:0.006523:0.005792:0.013143:0.007466:0.006523:0.011699:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330
therapy may include a degree of cardio-:@0.524249:0.422611:0.915172:0.422611:0.915172:0.406855:0.524249:0.406855:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.006427:0.018049:0.013143:0.010314:0.006427:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.006427:0.013143:0.006427:0.013181:0.012508:0.012950:0.005709:0.012508:0.012508:0.006427:0.012604:0.006042:0.006427:0.012450:0.013143:0.005677:0.013181:0.003848:0.012604:0.006388
toxicity, dermatitis and acute oesophagitis :@0.524249:0.438115:0.920499:0.438115:0.920499:0.422359:0.524249:0.422359:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330:0.004156:0.013181:0.012508:0.006321:0.018049:0.013143:0.006523:0.003848:0.006523:0.003848:0.007466:0.004156:0.013143:0.011738:0.013181:0.004156:0.013143:0.012450:0.011699:0.006523:0.012508:0.004156:0.012604:0.012508:0.007466:0.012604:0.013123:0.011738:0.013143:0.012950:0.003848:0.006523:0.003848:0.007466:0.005330
toxicity.:@0.524249:0.453620:0.594927:0.453620:0.594927:0.437864:0.524249:0.437864:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330
39:@0.594916:0.447994:0.607346:0.447994:0.607346:0.438808:0.594916:0.438808:0.006215:0.006215
Contra-indications, special  precautions :@0.542424:0.469115:0.920491:0.469115:0.920491:0.453360:0.542424:0.453360:0.015644:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.008986:0.007466:0.013123:0.012508:0.012450:0.003848:0.013143:0.003848:0.005330:0.003670:0.013123:0.005713:0.012508:0.012450:0.013143:0.011699:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
and drug interactions: See :@0.524240:0.484620:0.778586:0.484620:0.778586:0.468864:0.524240:0.468864:0.013143:0.011738:0.013181:0.006408:0.013181:0.005792:0.011699:0.012950:0.006408:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006408:0.009583:0.012508:0.012508:0.005330
MIMS Monthly, :@0.779663:0.484620:0.920479:0.484620:0.920479:0.468864:0.779663:0.468864:0.017684:0.004349:0.017684:0.009583:0.006408:0.017684:0.012604:0.011738:0.006523:0.011738:0.003848:0.010314:0.005330:0.005330
MDR:@0.524240:0.500125:0.567920:0.500125:0.567920:0.484369:0.524240:0.484369:0.017684:0.014316:0.011680
 or manufacturer’s product literature. :@0.567920:0.500125:0.918378:0.500125:0.918378:0.484369:0.567920:0.484369:0.005330:0.012604:0.005792:0.005330:0.018049:0.013143:0.011738:0.011699:0.006042:0.013143:0.012450:0.006523:0.011699:0.005694:0.012508:0.005792:0.006754:0.007466:0.005330:0.013123:0.005711:0.012604:0.013181:0.011699:0.012450:0.006523:0.005330:0.003848:0.003848:0.006523:0.012508:0.005792:0.013143:0.006523:0.011699:0.005698:0.012508:0.005330:0.005330
Ramucirumab:@0.524242:0.530566:0.670484:0.530566:0.670484:0.512545:0.524242:0.512545:0.012401:0.014111:0.020098:0.012828:0.013683:0.005131:0.006842:0.012828:0.020098:0.014111:0.014111
Ramucirumab is  a recombinant human :@0.524242:0.548685:0.920472:0.548685:0.920472:0.532929:0.524242:0.532929:0.011680:0.013143:0.018049:0.011699:0.012450:0.003848:0.005792:0.011699:0.018049:0.013143:0.013123:0.011488:0.003848:0.007466:0.005330:0.006171:0.013143:0.011488:0.005711:0.012508:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.011738:0.006523:0.011488:0.011738:0.011699:0.018049:0.013143:0.011738:0.005330
IgG1  monoclonal  antibody  that  specifi-:@0.524242:0.564190:0.915145:0.564190:0.915145:0.548434:0.524242:0.548434:0.004349:0.012950:0.016779:0.010660:0.005330:0.006171:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012592:0.011738:0.013143:0.003848:0.005330:0.006171:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.005330:0.006171:0.006523:0.011738:0.013143:0.006523:0.005330:0.006161:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.006388
cally binds to VEGFR2 and therefore Inhib-:@0.524242:0.579694:0.915130:0.579694:0.915130:0.563938:0.524242:0.563938:0.012450:0.013143:0.003848:0.003848:0.010314:0.005251:0.013123:0.003848:0.011738:0.013181:0.007466:0.005234:0.006523:0.012604:0.005234:0.013508:0.010314:0.016779:0.009333:0.011680:0.010660:0.005245:0.013143:0.011738:0.013181:0.005234:0.006523:0.011738:0.012508:0.005713:0.012508:0.006042:0.012604:0.005705:0.012508:0.005234:0.004349:0.011738:0.011738:0.003848:0.013123:0.006388
its ligand-induced proliferation, and mi-:@0.524242:0.595199:0.915132:0.595199:0.915132:0.579443:0.524242:0.579443:0.003848:0.006523:0.007466:0.011584:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.006388:0.003848:0.011738:0.013181:0.011699:0.012450:0.012508:0.013181:0.011584:0.013123:0.005715:0.012604:0.003848:0.003848:0.006042:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.011584:0.013143:0.011738:0.013181:0.011584:0.018049:0.003848:0.006388
gration  of human endothelial cells.  :@0.524242:0.610703:0.920481:0.610694:0.920481:0.594939:0.524242:0.594947:0.012950:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.012090:0.012604:0.006042:0.017434:0.011738:0.011699:0.018049:0.013143:0.011738:0.017434:0.012508:0.011738:0.013181:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.017434:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.018639:-0.325971
120:@0.896499:0.605075:0.915144:0.605075:0.915144:0.595890:0.896499:0.595890:0.006215:0.006215:0.006215
Ramucirumab  is indicated as a  single :@0.524241:0.626199:0.920498:0.626199:0.920498:0.610443:0.524241:0.610443:0.011680:0.013143:0.018049:0.011699:0.012450:0.003848:0.005792:0.011699:0.018049:0.013143:0.013123:0.005330:0.008744:0.003848:0.007466:0.014085:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.014085:0.013143:0.007466:0.014085:0.013143:0.005330:0.008746:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.005330
agent  or  in combination with paclitaxel, :@0.524241:0.641704:0.920481:0.641704:0.920481:0.625948:0.524241:0.625948:0.013143:0.012950:0.012508:0.011738:0.006523:0.005330:0.003723:0.012604:0.005792:0.005330:0.003723:0.003848:0.011738:0.009063:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.009063:0.015990:0.003848:0.006523:0.011738:0.009063:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.005330
for treatment of advanced gastric or gas-:@0.524241:0.657208:0.915160:0.657208:0.915160:0.641452:0.524241:0.641452:0.006042:0.012604:0.005792:0.005675:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005677:0.012604:0.006042:0.005684:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005696:0.012950:0.013143:0.007466:0.006523:0.005792:0.003848:0.012450:0.005684:0.012604:0.005792:0.005677:0.012950:0.013143:0.007466:0.006388
tro-oesophageal  junction  adenocarcino-:@0.524241:0.672713:0.915151:0.672713:0.915151:0.656957:0.524241:0.656957:0.006523:0.005709:0.012604:0.006388:0.012604:0.012508:0.007466:0.012604:0.013123:0.011738:0.013143:0.012950:0.012508:0.013143:0.003848:0.005330:0.003721:0.003906:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.003720:0.013143:0.013181:0.012508:0.011738:0.012604:0.012450:0.013143:0.005650:0.012450:0.003848:0.011738:0.012604:0.006388
ma, with disease progression on or after :@0.524241:0.688217:0.920471:0.688217:0.920471:0.672461:0.524241:0.672461:0.018049:0.013143:0.005330:0.008948:0.015990:0.003848:0.006523:0.011738:0.008948:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.008948:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.008948:0.012604:0.011738:0.008948:0.012604:0.005792:0.008948:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330
prior  fluoropyrimidine-  or  platinum-con-:@0.524241:0.703722:0.915154:0.703722:0.915154:0.687966:0.524241:0.687966:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.009744:0.004666:0.004666:0.011699:0.012604:0.005703:0.012604:0.013123:0.010314:0.005792:0.003848:0.018049:0.003848:0.013181:0.003848:0.011738:0.012508:0.006388:0.005330:0.009760:0.012604:0.005792:0.005330:0.009741:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.012450:0.012604:0.011738:0.006388
taining chemotherapy, in combination :@0.524241:0.719227:0.920490:0.719227:0.920490:0.703471:0.524241:0.703471:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.015355:0.012450:0.011738:0.012508:0.018049:0.012594:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.015355:0.003848:0.011738:0.015355:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
with docetaxel and for treatment of meta-:@0.524241:0.734731:0.915176:0.734731:0.915176:0.718975:0.524241:0.718975:0.015990:0.003848:0.006523:0.011738:0.004310:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.004310:0.013143:0.011738:0.013181:0.004310:0.006042:0.012604:0.005792:0.004301:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004310:0.012604:0.006042:0.004310:0.018049:0.012508:0.006523:0.013143:0.006388
static non-small-cell lung cancer with dis-:@0.524241:0.750236:0.915151:0.750236:0.915151:0.734480:0.524241:0.734480:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.007158:0.011738:0.012604:0.011738:0.006388:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.007170:0.003848:0.011699:0.011738:0.012950:0.007158:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007147:0.015990:0.003848:0.006523:0.011738:0.007158:0.013181:0.003848:0.007466:0.006388
ease progression on or after platinum-:@0.524241:0.765740:0.915158:0.765740:0.915158:0.749984:0.524241:0.749984:0.012508:0.013143:0.007466:0.012508:0.012892:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.012892:0.012604:0.011738:0.012892:0.012604:0.005792:0.012892:0.013143:0.006042:0.006523:0.012508:0.005792:0.012892:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388
based chemotherapy. Patients with EGFR :@0.524241:0.781245:0.920481:0.781245:0.920481:0.765489:0.524241:0.765489:0.013123:0.013143:0.007466:0.012508:0.013181:0.006592:0.012450:0.011738:0.012508:0.018049:0.012604:0.006512:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006581:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006581:0.015990:0.003848:0.006523:0.011738:0.006581:0.010314:0.016779:0.009333:0.011680:0.005330
or ALK genomic tumour aberrations should :@0.524241:0.796749:0.920479:0.796749:0.920479:0.780994:0.524241:0.780994:0.012604:0.005792:0.004256:0.014239:0.008890:0.011372:0.004256:0.012950:0.012508:0.011738:0.012604:0.018049:0.003848:0.012450:0.004256:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.004251:0.013143:0.013123:0.012508:0.005792:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.004260:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330
have disease progression on FDA-ap-:@0.524241:0.812254:0.915141:0.812254:0.915141:0.796498:0.524241:0.796498:0.011738:0.013143:0.010660:0.012508:0.016433:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.016433:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.016433:0.012604:0.011738:0.016433:0.009333:0.014316:0.014239:0.006388:0.013143:0.013123:0.006388
proved therapy for these aberrations prior :@0.524241:0.827759:0.920498:0.827759:0.920498:0.812003:0.524241:0.812003:0.013123:0.005715:0.012604:0.010660:0.012508:0.013181:0.005600:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005600:0.006042:0.012604:0.005792:0.005588:0.006523:0.011738:0.012508:0.007466:0.012508:0.005600:0.013143:0.013123:0.012508:0.005792:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005590:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330
to receiving ramucirumab. Ramucirumab :@0.524241:0.843263:0.920488:0.843263:0.920488:0.827507:0.524241:0.827507:0.006523:0.012604:0.006918:0.005713:0.012508:0.012450:0.012508:0.003848:0.010660:0.003848:0.011738:0.012950:0.006927:0.005792:0.013143:0.018049:0.011699:0.012450:0.003848:0.005792:0.011699:0.018049:0.013143:0.013123:0.005330:0.006927:0.011680:0.013143:0.018049:0.011699:0.012450:0.003848:0.005792:0.011699:0.018049:0.013143:0.013123:0.005330
may be used in combination with the FOL-:@0.524241:0.858768:0.915156:0.858768:0.915156:0.843012:0.524241:0.843012:0.018049:0.013143:0.010314:0.004791:0.013123:0.012508:0.004782:0.011699:0.007466:0.012508:0.013181:0.004782:0.003848:0.011738:0.004782:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.004778:0.015990:0.003848:0.006523:0.011738:0.004780:0.006523:0.011738:0.012508:0.004774:0.009333:0.016722:0.008890:0.006388
FIRI (folinic acid, 5-FU and irinotecan) regi-:@0.524241:0.874272:0.915137:0.874272:0.915137:0.858516:0.524241:0.858516:0.009333:0.004349:0.011680:0.004349:0.005336:0.007100:0.006042:0.012604:0.003848:0.003848:0.011738:0.003848:0.012450:0.005336:0.013143:0.012450:0.003848:0.013181:0.005330:0.005334:0.010660:0.006388:0.009333:0.012604:0.005334:0.013143:0.011738:0.013181:0.005336:0.003848:0.005792:0.003848:0.011738:0.012604:0.006523:0.012508:0.012450:0.013143:0.011738:0.007100:0.005334:0.005711:0.012508:0.012950:0.003848:0.006388
men, for the treatment of metastatic colo-:@0.524241:0.889777:0.915183:0.889777:0.915183:0.874021:0.524241:0.874021:0.018049:0.012508:0.011738:0.005330:0.004695:0.006042:0.012604:0.005792:0.004695:0.006523:0.011738:0.012508:0.004695:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004695:0.012604:0.006042:0.004695:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.004695:0.012450:0.012604:0.003848:0.012604:0.006388
rectal cancer  with  disease progression :@0.524241:0.905282:0.920483:0.905282:0.920483:0.889526:0.524241:0.889526:0.005713:0.012508:0.012450:0.006523:0.013143:0.003848:0.013681:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.008336:0.015990:0.003848:0.006523:0.011738:0.005330:0.008342:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.013681:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330
with or after prior therapy with bevacizum-:@0.524241:0.920786:0.915143:0.920786:0.915143:0.905030:0.524241:0.905030:0.015990:0.003848:0.006523:0.011738:0.004662:0.012604:0.005792:0.004655:0.013143:0.006042:0.006523:0.012508:0.005792:0.004657:0.013123:0.005792:0.003848:0.012604:0.005792:0.004655:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.004661:0.015990:0.003848:0.006523:0.011738:0.004662:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.006388
ab, oxaliplatin, and a fluoropyrimidine.:@0.524241:0.936291:0.882121:0.936291:0.882121:0.920535:0.524241:0.920535:0.013143:0.013123:0.005330:0.005330:0.012604:0.009236:0.013143:0.003848:0.003848:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.005330:0.013143:0.011738:0.013181:0.005330:0.013143:0.005330:0.004666:0.004666:0.011699:0.012604:0.005705:0.012604:0.013123:0.010314:0.005792:0.003848:0.018049:0.003848:0.013181:0.003848:0.011738:0.012508:0.005330
Biologicals:@0.795172:0.038601:0.914528:0.038601:0.914528:0.019343:0.795172:0.019343:0.013500:0.004704:0.015405:0.004704:0.015405:0.015828:0.004704:0.015216:0.016063:0.004704:0.009125